biostudies-literatureUnknown15(2)Liang X1q gain/amplification (1q+) is the most common cytogenetic abnormality (CA), with a frequency of 30-50% in patients with newly diagnosed multiple myeloma (NDMM). Although accumulating evidence supports 1q+ as a "high-risk" CA (HRCA), several issues remain to be addressed to understand its true prognostic property. We retrospectively analyzed a cohort of 934 patients with NDMM from three centers in China, who had baseline data available for 1q+ [including 1q21 gain (3 copies) and amplification (> 3 copies)] detected by fluorescence in situ hybridization in isolated CD138⁺ cells, and who received first-line treatment with novel agents including proteasome inhibitors, immunomodulatory drugs, or both. Minimal residue disease (MRD) was assessed using next-generation flow cytometry. IAmerican journal of cancer research501-516https://www.ebi.ac.uk/biostudies/studies/S-EPMC11897644biostudies-literatureDissecting the high-risk property of 1q gain/amplification in patients with newly diagnosed multiple myeloma.PMC11897644Yi XLiang XZhu YMa XZhang NLong MYan YSun XWang JSun YDai YJin FHuang WZhang YKumar SKLan MZhou FXu WHu RfalseDissecting the high-risk property of 1q gain/amplification in patients with newly diagnosed multiple myeloma.1q gain/amplification (1q+) is the most common cytogenetic abnormality (CA), with a frequency of 30-50% in patients with newly diagnosed multiple myeloma (NDMM). Although accumulating evidence supports 1q+ as a "high-risk" CA (HRCA), several issues remain to be addressed to understand its true prognostic property. We retrospectively analyzed a cohort of 934 patients with NDMM from three centers in China, who had baseline data available for 1q+ [including 1q21 gain (3 copies) and amplification (> 3 copies)] detected by fluorescence in situ hybridization in isolated CD138⁺ cells, and who received first-line treatment with novel agents including proteasome inhibitors, immunomodulatory drugs, or both. Minimal residue disease (MRD) was assessed using next-generation flow cytometry. I2025-01-01T00:00:00Z20252026-06-01T22:48:26.478Z2025-04-04T01:29:26.142ZS-EPMC118976444008436310.62347/fxvh442510.62347/FXVH4425